Hangzhou Tigermed Consulting Co., Ltd（stock symbol: 300347） is a leading Contract Research Organization (CRO) in China dedicated to provide professional full clinical trial services. Since inception in 2004, Tigermed has been committed to accelerating medical product development with costs efficiency and quality. Headquartered in Hangzhou, Tigermed operates 33 subsidiaries, 95 offices across China and 11 overseas offices in Hong Kong China, Taiwan China, USA, Switzerland, Korea, Australia, Japan, Malaysia, Singapore, India and Romania with over 4000 full time staffs. Tigermed has serviced more than 600 local and global clients in the conduct of over 1500 clinical trials. Tigermed is recognized as “The Innovative Clinical CRO” in China，owning to our involvement of over 160 innovative drugs.